Pharmaceuticals
Agilent and National Heart Centre Singapore Sign Agreement to Advance Metabolic Heart Failure Research
Research focuses on human cardiac organoids to uncover metabolic drivers of
heart failure and accelerate new therapeutic strategies to improve
cardiovascular outcomes
SINGAPORE, Nov. 13, 2025 /PRNewswire/ -- Agilent Technologies Inc.
2025-11-13 12:05
910
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinet...
2025-11-13 07:30
1314
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
863
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
2025-11-12 04:00
1214
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. andEurope was the driver of this strong performance. * United States: DKK 9,955 million (+22% CER; +19...
2025-11-12 03:11
1032
Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, "At this crucial juncture today,China's pharmaceutical innovation ...
2025-11-11 15:41
2008
Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigiousGold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings. The com...
2025-11-11 09:15
939
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successfu...
2025-11-11 09:00
953
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
2089
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...
2025-11-10 21:15
1089
MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("M ediTrustHealth") signed a strategic cooperation agreement. The...
2025-11-10 14:18
1174
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycer...
2025-11-10 12:00
1354
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee ...
2025-11-10 10:01
1362
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
* Findings provide scientific insights into the contribution of small
interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional
cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 /PRNewswire/ -- Brii
Biosciences Limited
2025-11-07 21:30
1604
EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients
The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: * The first two patients have now been enrolled in the WiSE-UP post-approval study by DrDevi Nair from St Bern...
2025-11-07 21:00
1001
Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
HONG KONG, Nov. 7, 2025 /PRNewswire/ -- On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted "The Asset Corporate Sustainability Leadership Awards 2025" ceremony inSingapore. Fosun International Limited ("Fosun International" or the "Company") (HKEX stock cod...
2025-11-07 09:00
2726
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders inSan Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-...
2025-11-06 12:05
988
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia
Patient, Demonstrating Excellent Safety and Significant Efficacy
SHANGHAI, Nov. 6, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai,
China, CorrectSequence Therapeutics Co., Ltd. (Correctseq
2025-11-06 08:00
1162
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and...
2025-11-05 18:00
1010
SingHealth Duke-NUS Launches Two New Global Health Centres to Advance Allied Health and Pharmacy Practices in Asia
* The Centre for Global Allied Health and Centre for Global Pharmacy will advance global health collaboration and capacity building, with a focus on strengthening allied health and pharmacy practices acrossAsia. * Both centres build on a legacy of more than 120 global health projects led by S...
2025-11-05 15:43
770
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4847
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
4093
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3950
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3868
